Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of bendazac lysine in the preparing process of medicine for preventing and treating diabetic nephropathy

A technology of benda lysine and diabetic nephropathy, which is applied in the application field of benda lysine in the preparation of drugs for the prevention and treatment of diabetic nephropathy, can solve the problems such as no benda lysine diabetic nephropathy, and achieve good results Medicinal prospects, strong action, clear dose-related effects

Active Publication Date: 2005-01-26
NANJING MEDICAL UNIV +1
View PDF0 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

So far, there is no relevant report that benzyl lysine can treat diabetic nephropathy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] Example 1: Effects of BDL on Blood Glucose and Renal Function in Rats with Diabetic Nephropathy

[0026] 1 Materials and methods

[0027] 1.1 Experimental animals SD strain rats, 8 weeks old, male, weighing 160-180 g, were provided by the Experimental Animal Center of Nanjing Medical University.

[0028] 1.2 Drugs and Reagents Bendazol Lysine was provided by Zhejiang Pinghu Shapuaisi Pharmaceutical Co., Ltd., streptozotocin (STZ) was purchased from Calbiochem Company, blood glucose testing kit was purchased from Zhejiang Dongou Bioengineering Co., Ltd., urinary albumin The radioimmunoassay kit was purchased from China Institute of Atomic Energy, Beijing,

[0029] 1.3 Method

[0030] 1.3.1 Modeling and experimental treatment

[0031] 85 rats were randomly divided into normal control group, DN model group, BDL high-dose treatment group, BDL medium-dose treatment group, BDL low-dose treatment group, epalrestat (EPS) positive drug treatment group, a total of 6 groups, ex...

Embodiment 2

[0048] Example 2 Antioxidative Effect of BDL on Diabetic Nephropathy Rats

[0049] 1 Materials and methods

[0050] The experimental animals, medicines and reagents are the same as those in Example 1. Cortex AGEs and serum AGEs were measured in the collected cortex samples and serum samples, as well as the contents of T-AOC, CAT activity and GSH in serum.

[0051] 1.2 Statistical processing (same as embodiment 1)

[0052] 2 results

[0053] 2.1 Effect of BDL on cortical AGEs and serum AGEs in DN rats

[0054] The relative content of AGEs in the renal cortex (AUF / mg cortex) and the relative content of AGEs in the serum (AUF / mg protein) of the rats in the DN model group were significantly higher than those of the normal control group, and there were significant differences between the two groups. Significant difference (P<0.01); the renal cortex AGEs and serum AGEs of the BDL low-dose treatment group were significantly decreased, with significant and very significant differen...

Embodiment 3

[0075] Example 3 The effect of BDL on the extracellular matrix of rats with diabetic nephropathy

[0076] 1 Materials and methods

[0077] Experimental animals, medicines and reagents are the same as in Example 1, and the collected cortex samples and serum samples are respectively measured for laminin.

[0078] 1.1 Extraction and determination of laminin

[0079] Blot dry the cryopreserved kidney cortex specimens to prepare homogenate (homogenate solution is 0.15mol / L NaCl, 0.05mol / L Tris-HCl, pH7.4), add 1mL extract solution (extract solution is HAc 0.5mol / L , pepsin 1g / L), extracted at 4°C for 18h, and the supernatant was taken to determine the content of laminin.

[0080] 1.2 Statistical processing (same as embodiment 1)

[0081] 2 results

[0082]Compared with the normal control group, the content of laminin (μg / g) in the kidney tissue of rats in the DN model group was significantly higher, and there were very significant differences between the two groups (P0.05); Th...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the use of human bendazac lysine in pharmaceutical industry, wherein the bendazac lysine possesses substantial actions for reducing hypoglycemia and saccharifying hemoglobin and urine protein, thus can be applied to the prevention and treatment of diabetes.

Description

1. Technical field [0001] The present invention relates to a new application of benzara lysine, in particular to the application of benzara lysine in the preparation of medicines for preventing and treating diabetic nephropathy. 2. Background technology [0002] Diabetic nephropathy (DN) refers to the renal manifestations of diabetic idiopathic systemic microangiopathy, which is the most common complication of diabetes and one of the leading causes of death in diabetic patients. Epidemiological surveys found that the standardized prevalence rate of diabetes in my country is 3.2%, which means that more than 50 million people in my country are currently facing the threat of diabetes. In my country, 93% of diabetic patients are type 2 diabetes, of which 40% Will develop into DN. It can be predicted that with the rapid improvement of people's living standards and the extension of life expectancy, the prevalence of diabetes in my country will continue to rise in the 21st century,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/00A61K31/415A61P3/10A61P13/12
Inventor 任宝华印晓星张银娣沈建平吴建伟
Owner NANJING MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com